Sugammadex and neuromuscular disease: a systematic review with assessment of reporting quality and content validity
Authors' conclusion
These uncontrolled observations (of mainly low to moderate quality and validity) do not allow confident assessment of the efficacy and safety of sugammadex for the reversal of NMBAs in patients with neuromuscular diseases.
Study context
- Population
- Patients (any age) with any neuromuscular disease receiving sugammadex for NMBA reversal; mostly myasthenia gravis patients receiving rocuronium126 observational reports
- Participants
- 386 patients
- Outcome
- TOFR returned to ≥0.9 (patients with neuromonitoring)
Methodological detailsreporting quality assessment, content validity assessment
- Reporting quality assessment
- Content validity assessment
Pooled result
As reported in the abstract
TOFR returned to ≥0.9 in 258 of 265 patients with neuromonitoring
97.4%
Further pooled results
Reporting quality: 23-point CARE checklist score (90 case reports)
- Median CARE checklist score (IQR 11-16)
- 13.5
Validity: 41-point validity checklist score (all 126 reports)
- Median validity checklist score (IQR 20-27)
- 23
- Scores were positively correlated
Safety
Adverse events (patients in whom adverse events were reported as present or absent)
- Adverse events in 14 of 332 patients
- 4.2%
Original publication
Sugammadex and neuromuscular disease: a systematic review with assessment of reporting quality and content validity. Br J Anaesth. Published 12 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →